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Background: Asthma is a major public health problem with a huge social and economic burden affecting 300
million people worldwide. Viral respiratory infections are the major cause of acute asthma exacerbations and may
contribute to asthma inception in high risk young children with susceptible genetic background. Acute
exacerbations are associated with decreased lung growth or accelerated loss of lung function and, as such, add
substantially to both the cost and morbidity associated with asthma.
Discussion: While the importance of preventing viral infection is well established, preventive strategies have not
been well explored. Good personal hygiene, hand-washing and avoidance of cigarette smoke are likely to reduce
respiratory viral infections. Eating a healthy balanced diet, active probiotic supplements and bacterial-derived
products, such as OM-85, may reduce recurrent infections in susceptible children. There are no practical anti-viral
therapies currently available that are suitable for widespread use.
Summary: Hand hygiene is the best measure to prevent the common cold. A healthy balanced diet, active
probiotic supplements and immunostimulant OM-85 may reduce recurrent infections in asthmatic children.
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Asthma is a major public health problem with a huge
social and economic burden affecting 300 million people
worldwide [1]. Viral respiratory infections are the major
cause of acute asthma exacerbations and contribute to
asthma inception in high risk young children with sus-
ceptible genetic background. A history of wheeze asso-
ciated with respiratory viral infections early in life is one
of the major risk factors for the later development of
asthma [2-7], together with sensitization to aeroallergens
in early life and a family history of asthma and allergies,
reflecting a genetic predisposition. Respiratory viral
infections are also the principal cause of asthma exacer-
bations in children and adults [8-13]. However, the ques-
tion of whether viral infections “select” susceptible hosts
or whether viral infections may induce asthma de novo* Correspondence: p.sly@uq.edu.au
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distribution, and reproduction in any mediumby “damaging” airways is not settled. In other words, do
viruses cause or simply unmask asthma?
Viral infections and innate immune responses
Respiratory viruses first infect nasal epithelial cells which
triggers an antiviral response. This response is driven by
type I (α/β) and III (λ) interferons (IFN) that are induced
following recognition of viral ribonucleic acid (RNA) by
pattern recognition receptors (PRRs). Toll-like receptors
(TLRs) are cell surface and endosomal PRRs, whilst the
RNA helicase receptors (RIG-I and MDA-5) and NOD-
like receptors (NOD2), detect viral RNA in the cyto-
plasm. Signalling via the PRRs activates transcription
factors (IRF-3, IRF-7, NF-κB), which lead to the produc-
tion and secretion of type I and III IFN. The IFNs then
bind to cell surface receptors to activate a separate path-
way leading to the production of interferon stimulated
genes (ISGs) which encode antiviral proteins that combat
infection, as well as PRRs and transcriptional factors
which further amplify IFN production. The respiratory
syncytial virus (RSV), human meta-pneumovirus (hMPV)
and human rhinovirus (HRV) are all single stranded
RNA viruses but engage differently with cell signallingtral Ltd. This is an Open Access article distributed under the terms of the
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are primarily detected by RIG-I in the cytoplasm [14,15].
RSV can also be detected by NOD2 [16]. HRV is endocy-
tosed by epithelial cells, and is therefore primarily
detected by TLR3 in the endosome early in the infection
process and by RIG-I and MDA-5 later in infection fol-
lowing upregulation of these PRRs [17]. The fusion (F)
protein of RSV is recognised by TLR4 at the epithelial
cell surface [18].
A successful antiviral response would see the infection
limited to the upper airway, as is the case clinically with
the majority of viral infections in healthy individuals.
Should such a response be deficient, then predominantly
upper-airway viral infections, such as HRV, may spread
to the lower airways, causing lower respiratory symp-
toms and an exacerbation of asthma in predisposed
individuals.
Abnormal innate antiviral immunity in asthmatics
While definitive data are yet to be produced, experi-
mental HRV infections in adult volunteers initially sug-
gested that asthmatics were more likely to develop
lower respiratory infections (LRI) than healthy adults, i.
e. less likely to be able to limit viral replication to the
upper airways [19,20]. Subsequent in vitro infection of
primary airway epithelial cells from asthmatic and
healthy adults with HRV have demonstrated that asth-
matic cells produce less IFN-β [21] and IFN-λ [22]
making them potentially more susceptible to infection,
slower to clear infection, and more susceptible to
virus-induced cell cytotoxicity. Deficiencies in the IFN-
α response of peripheral blood mononuclear cells and
plasmacytoid dendritic cells from asthmatic adults and
children has also been observed, in these particular
studies, in response to RSV, HRV [14,15] and Influenza
A [23]. It is likely that the overall impaired innate im-
mune response of the asthmatic airway epithelium is a
result of deficiencies in the antiviral response of both
epithelial cells and immune cells. Childhood, especially
infancy, is characterized by developmentally-regulated
deficiencies in innate and adaptive immunity [24]. Such
deficiencies are likely to increase the risk of viral LRI
in children, especially in those at high risk for asthma
and allergies.
Viral infections in children with asthma
Each year, at the end of summer, parents of asthmatic
children are concerned about acute asthma exacerba-
tions following a common cold, asking how to minimize
the risk during the winter viral season. It is a valid con-
cern as up to 70% of asthmatic children have an inter-
mittent or wheeze which is mostly symptomatic after
viral infections [25,26]. Asthmatics with exacerbation-
prone phenotype are susceptible to acute exacerbationsrequiring hospitalization or an unscheduled visit for
medical attention. Major risk factors for acute exacerba-
tions include previous acute exacerbation, allergy, young
age, poorly controlled asthma, and, in particular, viral re-
spiratory infections. Moreover, recent data suggests an
interaction between allergies and viral infections occurs
to increase the risk of asthma exacerbation [27]. Acute
exacerbations are associated with decreased lung growth
or accelerated loss of lung function and, as such, add
substantially to both the cost and morbidity associated
with asthma [28,29]. Viral respiratory infections are the
main cause of asthma exacerbations in children (80-
85%) and are a major risk factor for admission in hos-
pital every autumn [30-32]. HRV are the most common
viral agents [33]; Other respiratory tract viruses detected
in children with an asthma exacerbation include RSV, in-
fluenza, coronavirus, hMPV, parainfluenza virus, adeno-
virus, and bocavirus [34-36]. Current drugs for the
prevention and treatment of virus-induced exacerbation
of asthma are poorly effective and novel alternative ther-
apies are needed.
Role of respiratory viral infections in asthma inception
Much research interest has focused on the potential role
respiratory viral infections play in the inception of
asthma. It is well established that hospitalization for
RSV bronchiolitis is a risk factor for asthma during
childhood [37,38]. Epidemiological studies have shown
an increased risk of asthma with LRI caused by HRV. In
the Childhood Origin of Asthma (COAST) birth cohort
study, wheezing with RSV (odds ratio [OR], 2.6), HRV
(OR, 9.8), or both HRV and RSV (OR, 10) was asso-
ciated with increased asthma risk at age six years [7].
The Childhood Asthma Study (CAS) in Perth, Australia
showed that wheezing with HRV or RSV in the first year
of life was a risk factor (OR, 2.5) for current wheeze at
five years of age [4]. Infant birth about four months be-
fore the winter virus peak carried the highest risk of
developing asthma compared with birth 12 months be-
fore the peak [39]. The risk of asthma is increased by se-
vere LRI (sLRI), especially in the presence of allergic
sensitization in early life [4,25]. There appears to be a
synergistic interaction between viral infection and aller-
gic sensitization, suggesting a “two hit” model for induc-
tion of persistent asthma. These data also provide a
series of novel strategies for the primary prevention of
asthma by prevention of either allergic sensitization or
of sLRI in high risk children. This strategy is also sup-
ported in a study by Simoes et al. [40], in which the use
of palivizumab to prevent RSV infection decreased the
risk of recurrent wheezing in nonatopic premature
infants.
The crucial period, with respect to asthma initiation,
appears to be the first two to three years of life during
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proceeds at maximum rates. Pulmonary inflammation
resulting from atopy and sLRI occurring during this vul-
nerable time is hypothesized to perturb underlying tissue
differentiation programs, resulting in deleterious long
term effects on respiratory functions. As a result, there
is widespread belief amongst the paediatric respiratory
community that intervention measures that can lower
the frequency and/or intensity of sLRI in early life
amongst the high risk atopic subgroup of children are
likely to be successful at preventing asthma. If success-
ful, these strategies would have major implications for
reducing the high impact of this chronic disease on the
community [17,41,42].
Recent studies using culture-independent techniques
have challenged the long-held dogma that lungs are ster-
ile and have demonstrated that a microbiota community
exists in the lung [43-45]. The implications of these new
data are not clear, however new concepts and more re-
search is required. The resident microbiome is different
in the presence of respiratory disease [45,46]; therefore
interactions between respiratory viruses and the resident
pulmonary microbiome are postulated. The pulmonary
and gastrointestinal microbiota influence the immune
system and interventional approaches (by bacterial
immunostimulants, prebiotics and/or probiotics) to cre-
ate a healthy gut and respiratory microbiota are potential
strategies for the prevention of viral infections [45].
Preventing viral infections by non-immunologic methods
Children are important vectors for HRV transmission to
family members particularly siblings [47,48]. HRV shed-
ding peaks two to four days after infection and decreases
sharply thereafter, although nasal samples can be posi-
tive for rhinovirus for up to five weeks after a symptom-
atic infection [49].
There are three ways of common cold transmission in
children. First, inhalation of small particles aerosolized
by coughing; second, large particle droplets from saliva
expelled while sneezing; and third, self-inoculation of
one’s own conjunctivae or nasal mucosa after touching a
person or object contaminated with the cold viruses.
The first two methods are inefficient [50], while the
third is the most important method of transmission. The
mode of transmission could differ with age of the index
case, duration of contact, and other factors. Moreover,
there is some evidence that the daily activities of infected
people can lead to the contamination of environmental
surfaces with HRV e.g. light switches, telephone dial but-
tons and handsets [48].
Meticulous hand hygiene is the best measure to pre-
vent the common cold; frequent hand washing and avoid
touching one's nose and eyes [51-53]. The use of alco-
hol-based hand sanitizers is also effective [54,55]. Thepromotion of handwashing was associated with a 12-
34% reduction in respiratory-tract infections and colds
in child-care centres in the USA [56] Canada [57] and
Australia [58] and a 21% decrease in absences due to re-
spiratory illness in the school setting [56]. Hand hygiene
campaigns were also successful in reducing absenteeism
caused by influenza-like illnesses among schoolchildren
in Egypt [59]. Similar programs within families would be
expected to reduce transmission of HRV between family
members.
A recent Cochrane review which included data from
67 randomised controlled trials and observational stud-
ies, investigated the effectiveness of physical interven-
tions to reduce the spread of respiratory viruses. The
authors concluded that respiratory virus spread can be
reduced by hygiene measures (such as handwashing), es-
pecially around younger children and can reduce trans-
mission from children to other family members [51].
Controversy still exists and a newly published study
showed that an antiviral hand treatment used by adult
volunteers, recruited from a university community, did
not significantly reduce RV infection or RV-related com-
mon cold illnesses [60].
Asthmatic children should avoid close contact with
people who have colds especially during the first three
days of their illness. There is little evidence to support
the effectiveness of face masks to reduce the risk of viral
respiratory infections and consequently, the use of mask
is generally not recommended for prevention of com-
mon cold [51,61].
General immunologic strategies
Immune function and anti-viral defenses have a number
of components, both specific and non-specific. Asth-
matic children can improve their immune function by
following some simple advice including a healthy life
style with regular exercise, a balanced diet, adequate
sleep and avoiding environmental tobacco smoke, stress
and unnecessary antibiotics.
Exercise
Exercise has anti-inflammatory effects and in the long
term can protect the development of chronic diseases
and obesity [62]. Regular exercise of moderate-intensity
is associated with a reduced incidence of upper respira-
tory tract infection. However, long hours of intensive
training appear to make children more susceptible to
upper respiratory tract infections [63-65]. The recom-
mended means of aerobic exercise is walking, with an
optimal frequency of three to five days a week and an
optimal duration of 20 to 30 minutes of continuous ac-
tivity [66]. In a recent study, the IgA secretion rate was
negatively correlated with the incidence of infections
[67]. A recent randomized trial comparing meditation
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50 years and older found significant reductions in ARI
illness [68].
Diet
Malnutrition is the most common cause of immune de-
ficiency worldwide and a balanced diet is fundamental
for a healthy immune system. Vitamin D deficiency has
been associated with increased risk of infections, early-
life wheeze and reduced asthma control [69,70]. Vitamin
A derivatives are involved in the regulation of the im-
mune system and tissue inflammation as well as preven-
tion of respiratory infections [71]. Zinc, selenium and
other trace elements are necessary for function of both
innate and adaptive immune function. A high intake of
fruit and vegetables ensures adequate consumption of
nutrients and antioxidants and appears to be beneficial
for asthma. Although recent reviews have shown that
zinc [72], garlic [73], Echinacea purpurea [74] or Gin-
seng [75] supplementation for several months may re-
duce cold incidence, there is insufficient evidence to
recommend any vitamin or mineral supplementation in
the management of asthmatic children without nutrient
deficiency [76,77]. However, a large controlled trial
showed Echinacea was ineffective in reducing infection
rate or symptom severity of HRV infection in healthy
young adult volunteers [78]. Vitamin C supplementation
failed to reduce the incidence of colds in the general
population except in those exposed to short periods of
extreme physical stress [79]. Finally, it is worth remem-
bering that infants who are not breastfed have signifi-
cantly higher risk of respiratory, gastrointestinal, and
other infections, as breast milk is a biologically active
substance containing antimicrobial and immunomodula-
tory elements [80-82].
Sleep
Sleep and the circadian system exert a regulatory influ-
ence on immune functions. Sleep deprivation can affect
immune function in several ways including reduced nat-
ural killer cell activity, suppressed interleukin-2 produc-
tion and increased levels of circulating proinflammatory
cytokines [83,84]. There is also evidence for an enhanced
susceptibility to the common cold and pneumonia with
poor sleep efficiency [85,86].
Air pollution
Air pollutants (nitrogen dioxide, ozone, particulate mat-
ter) and environmental tobacco smoke (ETS) have long
been correlated with multiple adverse effects on the im-
mune system and susceptibility to viral respiratory tract
infections in children [87-90]. Studies in Europe and the
United States have shown that 40% of children live with
a smoker [34] and they have approximately twice therisk of contracting a serious respiratory tract infection in
early life [91]. Cigarette smoking leads to a longer dur-
ation of cough, greater frequency of abnormal ausculta-
tory findings during acute respiratory tract illness
[92,93] and higher risk for severe exacerbations [94].
Urinary leukotriene E4 levels identify children exposed
to ETS at high risk for asthma exacerbation [94].
Specific immunologic strategies
There is strong evidence that some pharmacological pre-
parations can help prevent viral infection by specific
effects on immune system. These results have been
promising with a hope that using these strategies can at-
tenuate the role of viruses in asthma inception.
Probiotics and prebiotics
Ancient physicians of the Middle East prescribed yogurt
for curing disorders of the stomach, intestines and for
stimulation of appetite. It is written in the old Persian
Testament that “Abraham owed his longevity to the con-
sumption of sour milk” [95]. The popularity of probio-
tics and intestinal microbiota significantly increased
when the Nobel Prize-winning Russian scientist Eli
Metchnikoff suggested in 1908 that the long life of Bul-
garian peasants resulted from their consumption of fer-
mented milk products [96]. The term probiotic, meaning
for life, is used for live micro-organisms (typically of the
bifidobacterium and lactobacillus species) administered
in adequate amounts which confer a beneficial physio-
logical effect on the host. Prebiotics are nutrients, in par-
ticular oligosaccharides, which foster the growth of
probiotics in the colon. The term synbiotics is used
when a product contains both probiotics and prebiotics
[97].
Up to 100 trillion bacteria from different species
colonize the human gut [98]. This microbiota partici-
pates in: host metabolism, vitamin synthesis, control of
epithelial cell growth, protection from infectious
microbes, and helps proper development and function of
the immune system. There is constant cross-talk be-
tween microbiota and gut-associated lymphoid tissue
(the largest lymphoid tissue of the human body which
contains more than 60% of all body lymphocytes) to es-
tablish mucosal immune tolerance in the gut. Common
mucosal immunity describes the phenomenon where im-
mune cells, especially regulatory T-cells, traffic to and
influence responses at other mucosal surfaces, including
the lungs [99]. Alteration in the microbiota composition
(dysbiosis) results in immunological dysregulation that
may underlie many human diseases such as inflamma-
tory diseases [100], obesity [101], allergy [102] and auto-
immunity [103].
Reduced bacterial diversity in the infant’s gastrointes-
tinal tract has been associated with an increased risk of
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asthma or atopic dermatitis [102]. In the first year of
life, especially the first few weeks, the microbiota of the
newborn is highly variable during this critical time of
post-natal maturation of the immune system. Micro-
biota is shaped by genetic and environmental factors
including: mode of delivery, neonates born by means of
vaginal delivery are exposed to mothers gut, skin, and
vaginal flora [104]; breast feeding and diet [105]; farm
or urban living [106]; vitamin D status [107]; and anti-
biotic consumption [98,108]. This knowledge stimulated
interest in the use of probiotics and prebiotics as the
intentional introduction or encouragement of specific
microbes to shape immune system development. Spe-
cifically, the microbiota can activate distinct tolerogenic
dendritic cells in the gut and through this interaction
can drive regulatory T-cell differentiation that modu-
lates both Th1 and Th2 responses inside and outside
the gut [109-111]. Probiotics have been successfully
used for the treatment of several gastrointestinal disor-
ders (viral and antibiotic-associated diarrhea, inflamma-
tory bowel disease) [112,113]. However, attempts to
prevent or treat allergic disorders such as eczema,
asthma and allergic rhinitis have had inconsistent
results [99,109,114-116].
There are a growing number of clinical trials using
probiotics for the prevention and management of re-
spiratory infections. While the precise mechanisms are
largely unknown, speculations include: probiotics com-
pete against pathogens; increase the barrier function in
respiratory epithelium; immunostimulatory effects by
enhancing cellular immunity with increased activity of
natural killer cells and macrophages in airways [117].
Probiotics reduce the frequency of gastrointestinal and
respiratory tract infections in children who attend day
care centres [118]. They have also been found to reduce
the incidence of ventilator-associated pneumonia, re-
spiratory infections in healthy and hospitalized children,
and reduce the duration of common cold symptoms
[119-122].
One study demonstrated that that daily probiotic sup-
plementation for six winter months in children three to
five years of age reduced the incidence of fever, coughing
and rhinorrhea by 32-43% with no notable adverse
events [123]. Probiotic combination with vitamins and
minerals also reduced the duration and severity of com-
mon cold [124]. A recent Cochrane review of 14 rando-
mised controlled trials showed that probiotics were
better than placebo in reducing the number of episodes
of acute upper respiratory infections (URIs) and redu-
cing antibiotic use, while there were no differences in
the mean duration of an episode and no increase in ad-
verse events [125]. Probiotic foods such as probiotic
milk or yogurt (functional foods) containing well-definedprobiotic strains may reduce the risk of catching the
common cold and represent a simple, safe, effective,
available and affordable method for preventing respira-
tory infections in children [112,120,126-131].
Although there are several clinical trials that showed
the preventive effect of probiotic, prebiotic [132] or syn-
biotics treatments [133] on respiratory infections, not all
studies are positive with some failing to show any signifi-
cant preventive effect [134]. To explain the different
results in clinical trials, it is of particular importance to
point out that the immunomodulatory capabilities of
probiotics are strain-dependent. Difference in dosage,
duration of intervention, population and environmental
background may also affect the results. One major limi-
tation in this field is that it is not possible to test just
how “probiotic” a particular preparation is. Technical
advances will be required before some of the apparent
discrepant results of studies can be resolved.
Immunostimulants
Several immunostimulants, including herbal extracts,
bacterial extracts, synthetic compounds, have been pro-
moted as increasing the immune defences of the respira-
tory tract. A recent Cochrane review included data from
35 placebo-controlled trials including 4060 participants
below the age of 18 years in which various types of
“immunostimulants” were used to reduce acute respira-
tory tract infections, involving either upper or lower air-
ways. The authors concluded that immunostimulants
reduced the incidence of acute respiratory infections by
40% on average in susceptible children, but that trial
quality was generally poor and a “high level of statistical
heterogeneity was evident”. A subgroup analysis focusing
on bacterial immunostimulants, including OM85, pro-
duced similar results with lower statistical heterogeneity
[135].
OM-85 BV (Broncho-Vaxom) is an immunostimulant
extracted from eight common bacterial pathogens of the
upper respiratory tract: Haemophilus influenzae, Diplo-
coccus pneumoniae, Klebsiella pneumoniae and ozaenae,
Staphylococcus aureus, Streptococcus pyogenes and viri-
dans, Neisseria catarrhalis and has been used in several
countries around the world for as long as 20 years [136].
Recent studies showed that OM-85 BV can reduce the
number of acute respiratory infections by 25% to 50%
compared with placebo in children with a history of re-
current infection [137]. Of particular interest, Razi et al.
showed that children between the age one and six years
with recurrent wheezing who were given OM-85 BV had
a 40% reduction in the rates of wheezing over the subse-
quent 12 months, compared to placebo (p < 0.001). In
addition, the duration of each wheezing attack was two
days shorter in the group given OM-85 BV than in the
group given placebo (p= 0.001) [138].
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lacking from human studies. However, recent data from
rodents shows that baseline regulatory T lymphocyte ac-
tivity in the airways can be boosted by microbe-derived
stimulation of the gut [139]. Bacterial immunostimulants
were also shown to enhance innate immunity (i.e. intensi-
fication of phagocytosis) and adaptive immunity [140].
Interferons
As discussed above, evidence exists for an impaired in-
nate immune response to respiratory viral infections in
asthmatics [141]. Entry of rhinovirus into normal epithe-
lial cells initiates a vigorous innate immune response
with IFN-β secretion and apoptosis induction. In
asthma, IFN-β and IFN-λ responses are impaired, result-
ing in viral replication, cell cytotoxicity, enhanced virion
shedding and increased susceptibility to common cold
[17,142]. Epithelial cells of asthmatic patients responded
to exogenous treatment with IFN-β exhibiting reduced
rhinovirus release (Cakebread, Xu et al. 2011; Jackson,
Sykes et al. 2011). If the proposed deficiency of type I
and III contribute to asthma exacerbations [21,22,143],
correcting this deficiency with exogenous interferons
would be a logical approach. The advantages of inter-
feron application include the broad spectrum of activity
with low risk of resistance development [47]. Prophylac-
tic intranasal recombinant IFN-α and IFN-β have been
shown to be effective against rhinovirus infection in
humans [144-146]. The results of these clinical trials are
awaited with interest [147,148]. However, the systemic
symptoms associated with severe viral infections, e.g. in-
fluenza, are associated with interferons, so careful dosing
may be required. Considering the occurrence of the local
side effects, neutropenia and cost, the use of long-term
prophylaxis with daily, intranasal administration of inter-
ferons is not feasible [144]. However, randomized clin-
ical trials using similar strategies are currently underway
in adults with chronic respiratory disease and the results
are keenly awaited.
Vitamin D
Vitamin D deficiency is a common worldwide problem
[149-150]. Beside importance for bone health, vitamin D
plays an important role in adequate function of both the
innate and adaptive immune systems including develop-
ment of dendritic cells and regulatory T lymphocytes
[151,152] production of antimicrobial proteins by airway
epithelium [153], modifying the effect of intestinal flora
on inflammatory disorders [107], and modulation of the
inflammatory response to viral infections [154]. Recent
reports suggest that vitamin D might play a role in the
recent increase in allergic disease [155-157]. Vitamin D
insufficiency has been associated with a higher incidence
of respiratory tract infection, wheezing illness in children[158], reduced asthma control [159], emergency depart-
ment visits, severe asthma exacerbations and hospitaliza-
tions [70,160]. In a recent study of 48 children from five
to 18 years of age, with newly diagnosed asthma, vitamin
D supplementation during the northern hemisphere
winter months (September to July) prevented declining
serum concentrations of 25(OH) D and reduced the risk
of asthma exacerbation triggered by acute respiratory
tract infections [161].
Macrolides
Macrolides possess anti-inflammatory and immunomodu-
latory properties extending beyond their antibacterial ac-
tivity [162]. Indeed, they can attenuate pro-inflammatory
cytokine production by bronchial epithelial cells, neutro-
phils and macrophages that may contribute to clinical
improvement in many patients with chronic airway in-
flammation [163-165]. Azithromycin has anti-rhinoviral
activity and can reduce HRV replication and release by
increasing interferon production from epithelial cells
[42,166,167]. Macrolide antibiotics inhibit RSV infection
in human airway epithelial cells [168]. A three weeks
treatment with clarithromycin in RSV bronchiolitis had
statistically significant effects on hospital length of stay
and rate of readmission to the hospital within six months
after discharge [169]. However, direct evidence of macro-
lides preventing respiratory viral infection in children
is lacking.
Anti-viral therapies
As the majority of respiratory viral infections in young
children are caused by HRV or RSV, we will briefly dis-
cuss anti-viral strategies to prevent HRV or RSV infec-
tions in asthmatic children. Because there are more than
100 serotypes of HRV, antiviral drugs are considered to
be more effective than vaccination. Antiviral agents have
been designed to inhibit rhinovirus attachment, entry to
the cell, viral uncoating, and RNA and protein synthesis
[47]. Table 1 shows how intervention strategies can be
targeted to various steps in the infective process.
Rhinovirus structure
HRV has the icosahedrally shaped capsid formed by 60
identical copies of viral capsid structural proteins VP1-4.
The capsid protects the single-stranded, positive sense
RNA genome. While HRV-A and -B most often induce a
self-limited upper respiratory infection, the recently dis-
covered HRV-C was associated with sLRIs in infants,
bronchiolitis, and asthma exacerbations in children
[170,171].
Prevention of attachment, entry and uncoating
HRV deposits on nasal or conjunctival mucosa and is
transported to the posterior nasopharynx by mucociliary
Table 1 The processes of rhinoviral infection and
preventive strategies
Process Preventive strategies











Enhancing immunity Balanced diet, interferons,
immunostimulants,
probiotics, breast milk,
Echinacea, garlic, zinc, ginseng
Table 2 Summary of interventions to prevent rhinoviral
infection in asthmatic children
Effectiveness Interventions





Likely to be beneficial Regular exercise, balanced diet,
adequate sleep, low psychological
stress
Prevention of air pollutions and
environmental tobacco smoke (ETS)
Second generation of antihistamines
Monoclonal antibodies:
Anti IgE, Anti IL-5
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of HRV uses intercellular adhesion molecule-1 (ICAM-
1) as their receptor [173] and the minor group attach to
low density lipoprotein (LDL) receptor and very-LDL
(VLDL) receptors on epithelial cells in the adenoid area
to bind and enter cells [174,175]. Viral attachment can
be prevented by specific anti-HRV neutralizing anti-
bodies, anti-receptor antibodies and soluble receptor
molecules.
Endothelial cells express histamine receptors and
increased adhesion molecule expression, such as ICAM-
1, was demonstrated by histamine infusion. Second-gen-
eration H1-antihistamines decrease expression of
ICAM-1 on cultured bronchial epithelial cells [176].
Zinc may also act as an antiviral agent by reducing
ICAM-1 levels [177].
The monoclonal antibody to the cellular ICAM-1 was
not effective. CFY196 (Coldsol) is a nasal spray multiva-
lent Fab fusion proteins against ICAM-1 with a better
avidity and in vitro potency against HRV [178]. Trema-
camra, a soluble intercellular adhesion molecule 1
reduced the severity of experimental rhinovirus infection
[179]. Pleconaril, an orally administered antiviral drug,
acts by binding to a hydrophobic pocket in viral protein
1, and stabilizes the protein capsid so that the virus can-
not release its RNA genome into the target cell. Out-
comes of clinical trials with pleconaril have revealed
mixed results and new compounds are currently being








Unlikely to be beneficial Mask
Vaccination
Likely to be ineffective or harmful Antibiotics
Intensive exercisePrevent RNA and protein synthesis
Despite extensive research, no agent has been approved
for prevention and/or therapy of rhinovirus-induced dis-
eases so far. Ruprintrivir selectively inhibits HRV 3C
protease and shows potent, broad-spectrum anti-HRV
activity in vitro. Ruprintrivir nasal spray (2% solution)
prophylaxis reduced the proportion of subjects with
positive viral culture by 26% and reduce viral titers, but
did not decrease the frequency of colds [181]. HRVRNA synthesis during replication can be blocked by
deoxyribozymes [182], morpholino oligomers [183], and
small interfering ribonucleic acids [184]. The novel anti-
viral therapies that have been discovered recently, may
one day add significantly to the armamentarium of anti-
viral agents, against respiratory viral infections in asth-
matic children.
Monoclonal antibodies
Maternally-derived RSV neutralizing antibodies help to
protect infants against RSV hospitalization [185]. Palivi-
zumab, a humanised monoclonal antibody against the
RSV fusion protein is effective against RSV and wheezing
in children and reduces hospitalization in high-risk indi-
viduals [185,187]. RSV prophylaxis with palivizumab sig-
nificantly reduced the relative risk of subsequent
recurrent wheezing in nonatopic premature infants [40].
Motavizumab is another monoclonal antibody against
RSV, with an approximately 20-fold increase in ability to
neutralize RSV and 100 fold increase in ability to reduce
viral titers compared to palivizumab [188,189]. Motavi-
zumab was also found to be superior to palivizumab in
reducing outpatient medically attended lower respiratory
illness by 50% [190].
Vaccination
Vaccination against HRV and RSV have been in develop-
ment for quite some time, but there are no safe and effect-
ive vaccines at present [33,191]. High rates of exposure to
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of HRV, the presence of maternal antibodies, the risk of
vaccine induced disease and relative immaturity of the in-
fant immune system make effective vaccination difficult
[186,192,193].
Discussion
Respiratory viral infections are major contributors to the
global burden imposed by asthma. In early life, they con-
tribute to the inception of asthma and are responsible
for most of the acute exacerbations for asthma in child-
hood. While the debate is not completely settled, chil-
dren at high risk of developing asthma and those with
established asthma may be at increased risk of acquiring
respiratory viral infections and may be less able to con-
tain these to the upper airway. Several simple general
strategies can be used to help prevent respiratory viral
infections in asthmatic children (Table 2), with good per-
sonal hygiene, hand-washing and avoidance of cigarette
smoke likely to reduce respiratory viral infections. Gen-
eral immuno-stimulatory strategies, such as eating a
healthy balanced diet, active probiotic supplements and
bacterial-derived products, e.g. OM-85, may reduce re-
current infections in susceptible children.
Summary
While research continues on specific anti-viral therap-
ies, including vaccination, there are no currently avail-
able practical therapies that are suitable for widespread
use. The role of preventative strategies in primary pre-
vention of asthma in high risk children is of consider-
able academic interest and a number of studies are
currently in the pipeline. The results are awaited with
interest.
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